Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SON-080 in persistent CIPN
NCT05435742Phase 2Terminated
- Sponsor
- Sonnet BioTherapeutics
- Start
- Oct 2022
- Primary completion
- Mar 2024
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of atexakin alfa in chemotherapy-induced peripheral neuropathy (CIPN) (3 arms), sponsored by Sonnet BioTherapeutics. Primary endpoint: Evaluate the safety of SON-080 at 24 weeks. Started Oct 2022; status: terminated.
02
Drugs
atexakin alfa
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT05435742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05435742.